Halley E. Gilbert

CIK: 0001601360

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (12.5%)

Position reduction

Option Exercises (M)1 (12.5%)

Derivative conversions

Awards (A)6 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

CTMX

CytomX Therapeutics, Inc.

Director

PCVX

Vaxcyte, Inc.

Director

ARQT

Arcutis Biotherapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

CTMX
CytomX Therapeutics, Inc.
Jun 17, 2026
Award(A)
Stock Option (Right to Buy)
Direct
59K shares-
PCVX
Vaxcyte, Inc.
Jun 15, 2026
Award(A)
Direct
2.3K shares-
ARQT
Arcutis Biotherapeutics, Inc.
Jun 5, 2026
Award(A)
Direct
5.8K shares-
ARQT
Arcutis Biotherapeutics, Inc.
Nov 20, 2025
Exercise(M)
Direct
12.2K shares at avg. $7.51$92K
ARQT
Arcutis Biotherapeutics, Inc.
Nov 20, 2025
Sale(S)
Direct
16.5K shares at avg. $27.55$455K
ARQT
Arcutis Biotherapeutics, Inc.
Jun 12, 2025
Award(A)
Direct
7.6K shares-
PCVX
Vaxcyte, Inc.
Jun 12, 2025
Award(A)
Direct
3K shares-
CTMX
CytomX Therapeutics, Inc.
Jun 11, 2025
Award(A)
Stock Option (Right to Buy)
Direct
38K shares-

		Type	Shares	Price		Ownership
Jun 17, 2026	CTMX CytomX Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	59,000	-	-	Direct
Jun 15, 2026	PCVX Vaxcyte, Inc.	Award(A)	2,265	-	$0	Direct
Jun 5, 2026	ARQT Arcutis Biotherapeutics, Inc.	Award(A)	5,778	-	$0	Direct
Nov 20, 2025	ARQT Arcutis Biotherapeutics, Inc.	Exercise(M)	12,220	$7.51	$91,772	Direct
Nov 20, 2025	ARQT Arcutis Biotherapeutics, Inc.	Sale(S)	16,532	$27.55	$455,442	Direct
Jun 12, 2025	ARQT Arcutis Biotherapeutics, Inc.	Award(A)	7,609	-	-	Direct
Jun 12, 2025	PCVX Vaxcyte, Inc.	Award(A)	3,041	-	-	Direct
Jun 11, 2025	CTMX CytomX Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	38,000	-	-	Direct

1-8 of 8 transactions

About Gilbert Halley E

Gilbert Halley E (SEC CIK 0001601360) files insider reports with the SEC as Director of CytomX Therapeutics, Inc. (CTMX), Director of Vaxcyte, Inc. (PCVX) and Director of Arcutis Biotherapeutics, Inc. (ARQT).

Signal8 holds 7 ownership filings by Gilbert Halley E, all Form 4s, filed between Jun 13, 2025 and Jun 22, 2026. Those filings report 8 transactions, from Jun 11, 2025 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Gilbert Halley E's filings is in WESTLAKE VILLAGE, CA.

Recent filings by Gilbert Halley E

Jun 17, 2026: Grant or award of CTMX derivative securities (Form 4, code A).
Jun 15, 2026: Grant or award of PCVX shares (Form 4, code A).
Jun 5, 2026: Grant or award of ARQT shares (Form 4, code A).
Nov 20, 2025: Option exercise of ARQT shares (Form 4, code M).
Nov 20, 2025: Open-market sale of ARQT shares (Form 4, code S).

Other insiders filing for CytomX Therapeutics, Inc. (CTMX)

McCarthy Sean A., CEO
Carvajal Alejandra, Chief Legal Officer
Fuchs Charles S., Director
Su Zhen, Director
Young Matthew P., Director
Mohindru Mani, Director

How to read Form 4 transaction codes